Supplemental Annuity Collective Trust of NJ Has $4,225,000 Stake in Johnson & Johnson (JNJ)

Supplemental Annuity Collective Trust of NJ maintained its stake in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,934 shares of the company’s stock at the close of the 2nd quarter. Johnson & Johnson accounts for about 1.9% of Supplemental Annuity Collective Trust of NJ’s portfolio, making the stock its 8th largest position. Supplemental Annuity Collective Trust of NJ’s holdings in Johnson & Johnson were worth $4,225,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Ironwood Investment Management LLC lifted its position in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Ironwood Investment Management LLC now owns 5,074 shares of the company’s stock worth $671,000 after purchasing an additional 20 shares during the period. Welch Investments LLC lifted its position in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Welch Investments LLC now owns 35,107 shares of the company’s stock worth $4,644,000 after purchasing an additional 1,190 shares during the period. Peoples Bank OH lifted its position in shares of Johnson & Johnson by 2.7% in the 2nd quarter. Peoples Bank OH now owns 9,440 shares of the company’s stock worth $1,249,000 after purchasing an additional 250 shares during the period. Grove Bank & Trust lifted its position in shares of Johnson & Johnson by 66.1% in the 2nd quarter. Grove Bank & Trust now owns 5,187 shares of the company’s stock worth $686,000 after purchasing an additional 2,065 shares during the period. Finally, Bessemer Group Inc. lifted its position in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Bessemer Group Inc. now owns 2,137,947 shares of the company’s stock worth $282,828,000 after purchasing an additional 19,989 shares during the period. 66.06% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on the stock. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a research report on Monday, September 18th. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $143.70.

ILLEGAL ACTIVITY NOTICE: “Supplemental Annuity Collective Trust of NJ Has $4,225,000 Stake in Johnson & Johnson (JNJ)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/06/supplemental-annuity-collective-trust-of-nj-has-4225000-stake-in-johnson-johnson-jnj.html.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $140.08 on Monday. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $376,327.72, a price-to-earnings ratio of 19.62, a PEG ratio of 2.85 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the business posted $1.68 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s payout ratio is 58.33%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit